Rchr
J-GLOBAL ID：202001016468456940
Update date: Mar. 06, 2024
Goyama Susumu
ゴウヤマ ススム | Goyama Susumu
Affiliation and department：
Job title：
教授
Research field (1)：
Hematology and oncology
Research keywords (5)：
Tumor Immunity
, Transcription Factor
, Epigenetics
, Hematological Malignancies
, Leukemia
Research theme for competitive and other funds (15)：
- 2022 - 2026 Identification of tumor driver lncRNAs in myeloid tumors and development of lncRNA-targeting therapies
- 2022 - 2025 骨髄系腫瘍におけるドライバーlncRNAの同定とlncRNA標的医薬の開発
- 2022 - 2024 膜のない構造体パラスペックルの生体内での役割と生物学的意義の解明を目指して
- 2022 - 2024 Identification of the cell of origin of infant leukemia with pluripotency
- 2021 - 2023 Development of proteostasis modulators targeting the co-chaperon E3 ligase STUB1
- 2020 - 2023 Ab initio法を活用した造血系腫瘍におけるlncRNAの統合的機能解析
- 2019 - 2023 Targeting transcription and epigenetic factors through modulation of protein-protein interactions
- 2019 - 2021 Crosstalk between clonal hematopoiesis and solid tumors
- 2018 - 2020 Analyses of relationship between clonal hematopoiesis associated with leukemia-related gene mutations and leukemia/solid tumors/cardiovascular diseases
- 2017 - 2019 Ab initio analysis on the pathophysiology of hematopoietic neoplasms
- 2016 - 2018 Crosstalk between epigenetic therapy and anti-tumor immunity in the treatment of hematopoietic neoplasms
- 2015 - 2016 造血系転写因子RUNX1のユビキチン化修飾および分解制御機構の解明
- 2008 - 2009 Establishment of experimental model for leukemia to develop novel molecular therapy
- 2006 - 2007 Evi1による造血幹細胞及び癌化の制御機構
- 2005 - 2006 Comprehensive analysis of oncogenic transcriptional factor Evi-1.
Show all
Papers (96)：
-
Muran Xiao, Shinji Kondo, Masaki Nomura, Shinichiro Kato, Koutarou Nishimura, Weijia Zang, Yifan Zhang, Tomohiro Akashi, Aaron Viny, Tsukasa Shigehiro, et al. BRD9 determines the cell fate of hematopoietic stem cells by regulating chromatin state. Nature communications. 2023. 14. 1. 8372-8372
-
Tomohiro Yabushita, Takumi Chinen, Atsuya Nishiyama, Shuhei Asada, Ruka Shimura, Tomoya Isobe, Keita Yamamoto, Naru Sato, Yutaka Enomoto, Yosuke Tanaka, et al. Mitotic perturbation is a key mechanism of action of decitabine in myeloid tumor treatment. Cell reports. 2023. 42. 9. 113098-113098
-
Yuta Kaito, Emi Sugimoto, Fumi Nakamura, Yutaka Tsukune, Makoto Sasaki, Shunsuke Yui, Hiroki Yamaguchi, Susumu Goyama, Yasuhito Nannya, Kinuko Mitani, et al. Immune checkpoint molecule DNAM-1/CD112 axis is a novel target for NK-cell therapy in acute myeloid leukemia. Haematologica. 2023
-
Kazuya Miyashita, Takuya Yagi, Noritaka Kagaya, Azusa Takechi, Chihiro Nakata, Risa Kanda, Hideko Nuriya, Kosuke Tanegashima, Shota Hoyano, Fumiya Seki, et al. Identification of compounds that preferentially suppress the growth of T-cell acute lymphoblastic leukemia-derived cells. Cancer Science. 2023. 114. 10. 4032-4040
-
Taishi Yonezawa, Hirotaka Takahashi, Yangying Hao, Chie Furukawa, Akiho Tsuchiya, Wenyu Zhang, Tsuyoshi Fukushima, Tomofusa Fukuyama, Tatsuya Sawasaki, Toshio Kitamura, et al. The E3 ligase DTX2 inhibits RUNX1 function by binding its C terminus and prevents the growth of RUNX1-dependent leukemia cells. The FEBS journal. 2023
ｍore...
MISC (24)：
-
田中洋介, 田中洋介, 福島剛, 小出周平, 合山進, 岩間厚志, 須田年生, 北村俊雄. The hematopoietic stem cell picture based on their division patterns. 日本再生医療学会総会(Web). 2023. 22nd
-
Yasutaka Hayashi, Kimihito Cojin Kawabata, Yosuke Tanaka, Yasufumi Uehara, Shigeru Kiryu, Yasunori Ota, Yusuke Yoshioka, Yo Mabuchi, Tatsuki Sugiyama, Keiko Mikami, et al. Impaired Osteoblastic Differentiation of MSCs Suppresses Normal Hematopoiesis in MDS. BLOOD. 2020. 136
-
米澤大志, 高橋宏隆, 澤崎達也, 北村俊雄, 合山進. DTX2はRUNX1のユビキチン化および脱アセチル化を促進し,白血病細胞の増殖を抑制する. 日本血液学会学術集会抄録(Web). 2020. 82nd
-
藤野赳至, 越智陽太郎, 昆彩奈, 合山進, 小川誠司, 北村俊雄. Asxl1変異とStag2の欠失は協調してクロマチン構造を開き骨髄異形成症候群の発症を誘導する. 日本血液学会学術集会抄録(Web). 2020. 82nd
-
Taishi Yonezawa, Hirotaka Takahasi, Tatsuya Sawasaki, Toshio Kitamura, Susumu Goyama. The Ubiquitin Ligase DTX2 Promotes Nuclear Export of RUNX1 and Inhibits RUNX1-Dependent Leukemogenesis. BLOOD. 2019. 134
ｍore...
Education (2)：
- 2002 - 2006 Graduate School of Medicine and Faculty of Medicine
- 1993 - 1999 The University of Tokyo Graduate School of Medicine and Faculty of Medicine
Professional career (1)：
Work history (10)：
- 2020/04 - 現在 Graduate School of Frontier Sciences, The University of Tokyo Division of Molecular Oncology Professor
- 2015/03 - 2020/03 The Institute of Medical Science, The University of Tokyo Division of Cellular Therapy Associate Professor
- 2012/04 - 2015/02 Cincinnati Children’s Hospital Medical Center Experimental Hematology and Cancer Biology Research Associate
- 2010/04 - 2012 Cincinnati Children’s Hospital Medical Center Postdoctoral Fellow for Research Abroad
- 2009/07 - 2010/03 Cincinnati Children’s Hospital Medical Center Division of Experimental Hematology and Cancer Biology
- 2009/02 - 2009/06 The University of Tokyo Hospital Assistant professor
- 2006/04 - 2008/01 The University of Tokyo Hospital Department of Hematology and Oncology Senior Residency
- 2001/04 - 2002/03 The University of Tokyo Hospital Department of Hematology and Oncology Senior Residency
- 2000/06 - 2001/03 The Ibaragi Hitachi Hospital, Ibaragi, Japan Residency, the Ibaragi Hitachi Hospital, Ibaragi, Japan
- 1999/06 - 2000/05 The University of Tokyo Hospital Residency
Show all
Association Membership(s) (2)：
Japanese Cancer Association
, Japan Society of Hematology
